Pricing Log in Create free account

Spero Therapeutics, Inc. (SPRO) vs XBiotech Inc. (XBIT)

Spero Therapeutics, Inc. and XBiotech Inc. are both Biotechnology companies. Spero Therapeutics, Inc. and XBiotech Inc. are of similar size ($65.9M and $65.8M). XBiotech Inc. has negative trailing earnings, so its P/E is not meaningful; Spero Therapeutics, Inc. trades at 7.9×. Spero Therapeutics, Inc. grew revenue faster over the last twelve months: 37.2% against −78.2%. Across the 14 metrics below, Spero Therapeutics, Inc. leads on 10 and XBiotech Inc. on 4.

Valuation

Metric SPRO XBIT Biotechnology median
P/E 7.86 n/m 8.50
P/S 1.04 16.12 9.71
P/B 1.44 0.50 2.13
Price to free cash flow 3.26 n/m 20.82
EV/EBITDA 2.16 0.74 0.64
EV/Sales 0.21 (8.64) 9.21
Earnings yield 12.73% (69.81%) (33.15%)
Free cash flow yield 30.65% (63.41%) (25.50%)

Profitability

Metric SPRO XBIT Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 19.17% (29.94%) (56.36%)
Return on assets 12.85% (28.90%) (48.04%)
Return on invested capital 0.00% (159.18%) 0.00%

Growth

Metric SPRO XBIT Biotechnology median
Revenue growth (TTM) 37.24% (78.20%) 6.02%
EPS growth (last fiscal year) 111.81% (18.25%) 30.26%
Revenue growth, 5-year CAGR 48.25% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric SPRO XBIT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.12 33.15 4.72
Net debt to EBITDA (6.38) 2.33 0.96

Dividend

Metric SPRO XBIT Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric SPRO XBIT Biotechnology median
Market cap 65.80m 65.85m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack